Showing results (81-90 of 99) with videos related to
Sort By:
Pageof 10
Environmental Microbiome|June 4, 2026
The microecological mechanism of Cordyceps chanhua promoting soil nitrogen cyclingGongping Hu, Youcui Yang, Tao Wang, et al.Hematological Oncology|December 14, 2022
15-days duration of venetoclax combined with azacitidine in the treatment of relapsed/refractory high-risk myelodysplastic syndromes: A retrospective single-center studyChen Mei, Li Ye, Yanling Ren, et al.Leukemia & Lymphoma|October 11, 2018
Clinical and biological characteristics of acute myeloid leukemia with 20-29% blasts: a retrospective single-center studyChen Mei, Yanling Ren, Xinping Zhou, et al.Cancer Science|December 6, 2019
Mutation status and burden can improve prognostic prediction of patients with lower-risk myelodysplastic syndromesLingxu Jiang, Yingwan Luo, Shuanghong Zhu, et al.Journal of Cancer Research and Clinical Oncology|March 18, 2018
Isocitrate dehydrogenase 2 mutations correlate with leukemic transformation and are predicted by 2-hydroxyglutarate in myelodysplastic syndromesPeipei Lin, Yingwan Luo, Shuanghong Zhu, et al.Cancer Medicine|February 20, 2021
Clinical significance of cytogenetic and molecular genetic abnormalities in 634 Chinese patients with myelodysplastic syndromesXuefen Yan, Lu Wang, Lingxu Jiang, et al.Hematological Oncology|May 30, 2020
Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trialXinping Zhou, Chen Mei, Jin Zhang, et al.The Journal of Clinical Investigation|February 22, 2024
Ectopic expression of the transcription factor ONECUT3 drives a complex karyotype in myelodysplastic syndromesYingwan Luo, Xiaomin Feng, Wei Lang, et al.Science Advances|April 17, 2024
RIPK3 deficiency blocks R-2-hydroxyglutarate-induced necroptosis in IDH-mutated AML cellsShuanghong Zhu, Yingwan Luo, Kongfei Li, et al.Hematological Oncology|February 3, 2025
Moderate-To-Severe Bone Marrow Fibrosis Is an Independent Risk Factor For Myelodysplastic Neoplasms Patients With Increased BlastsGaixiang Xu, Xingnong Ye, Yudi Zhang, et al.Pageof 10